T3S's secretion platform is based on high-level expression followed by true secretion of proteins and will allow Vectron to boost its protein production offering, according to the company. Dynamk Capital, a growth equity and venture capital firm, led the financing round, Vectron said.

Senda accelerates drug development platform with $98M in new funding
Senda Biosciences announced it has closed $98 million in financing to bring the company's platform and its therapeutic programs into clinical trials.

August Bioservices raises $24M to grow U.S. manufacturing
August Bioservices has raised about $24 million in funding to expand its biomanufacturing capabilities in the U.S.

Engine Biosciences raises $43M for combo genetic platform
Engine Biosciences has raised $43 million to advance its drug discovery and development platform, which uses next-generation combinatorial genetics...

IsoPlexis acquires sequencing methodology IP
IsoPlexis has acquired an intellectual property (IP) portfolio of 86 patents related to DNA and RNA sequencing, which it is integrating into its single-cell...

BioTheryX secures $92M to advance protein degradation oncology pipeline
BioTheryX announced it has secured $92 million in series E financing to advance multiple molecular glues, proteolysis-targeting chimeras, and monovalent...